 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...5556575859606162636465...6970» |
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Heterogeneity: T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (clinicaltrials.gov) - Jan 15, 2019
P2, N=164, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting
- | New P3 trial, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jan 13, 2019
P3, N=400, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Metastases: CLEOPATRA: A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 8, 2019
P3, N=808, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: CARE-B: CARdiac Function Evaluation in Breast Cancer Patients (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=25, Recruiting, Sponsor: Swansea University
Active, not recruiting --> Completed Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Dec 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 27, 2018
P2, N=130, Recruiting, Sponsor: Southwest Oncology Group
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
New P3 trial, PD(L)-1 Biomarker, Metastases: APTneo: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 22, 2018
P3, N=650, Not yet recruiting, Sponsor: Fondazione Michelangelo
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: SAFE-HEaRt: Cardiac Safety Study in Patients With HER2 + Breast Cancer (clinicaltrials.gov) - Dec 21, 2018
P2, N=30, Active, not recruiting, Sponsor: Washington Hospital Center
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Dec 2020 Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Aug 2017 --> Jan 2019
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker: IMpassion050: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (clinicaltrials.gov) - Dec 20, 2018
P3, N=224, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Aug 2017 --> Jan 2019 Not yet recruiting --> Recruiting
- ||| Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) - Dec 19, 2018
P2, N=144, Recruiting, Sponsor: International Breast Cancer Study Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Dec 6, 2018
P=N/A, N=135, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Feb 2020 | Trial primary completion date: Dec 2020 --> Feb 2020
- | Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 6, 2018
P1b, N=99, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2020 --> Feb 2020 | Trial primary completion date: Dec 2020 --> Feb 2020 Trial completion date: Jan 2027 --> Jan 2026
- ||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 5, 2018
P2, N=32, Terminated, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jan 2027 --> Jan 2026 Trial completion date: Mar 2020 --> Dec 2016 | Active, not recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016; The study terminated early due to weak accrual.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 4, 2018
P2, N=69, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Mar 2020 --> Dec 2016 | Active, not recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016; The study terminated early due to weak accrual. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: BrUOG 308: Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. (clinicaltrials.gov) - Nov 29, 2018
P2, N=30, Recruiting, Sponsor: William Sikov MD
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Feb 2019
- | Perjeta (pertuzumab) / Roche
Clinical, P3 data, Journal: Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. (Pubmed Central) - Nov 28, 2018
P3
Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus HER2-targeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group. Further efforts to improve the efficacy of chemotherapy without imparting more toxicity are warranted.
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (clinicaltrials.gov) - Nov 20, 2018
P2, N=174, Not yet recruiting, Sponsor: Cedars-Sinai Medical Center
- | Opdivo (nivolumab) / Ono Pharma, BMS
New P2 trial: Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) (clinicaltrials.gov) - Nov 15, 2018
P2, N=52, Not yet recruiting, Sponsor: New York University School of Medicine
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date: Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer (clinicaltrials.gov) - Nov 8, 2018
P2, N=75, Not yet recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Further efforts to improve the efficacy of chemotherapy without imparting more toxicity are warranted. Initiation date: Sep 2018 --> Dec 2018
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Nov 6, 2018
P2, N=65, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: Sep 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC (clinicaltrials.gov) - Nov 6, 2018
P1, N=100, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
New P3 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: IMpassion050: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (clinicaltrials.gov) - Nov 1, 2018
P3, N=224, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: HERACLES RESCUE: Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 30, 2018
P2, N=54, Active, not recruiting, Sponsor: Fondazione del Piemonte per l'Oncologia
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? (clinicaltrials.gov) - Oct 29, 2018
P=N/A, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- | Trial completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 26, 2018
P2a, N=765, Recruiting, Sponsor: Genentech, Inc.
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Trial completion date: Aug 2020 --> Mar 2021
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial: DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC (clinicaltrials.gov) - Oct 22, 2018
P1, N=100, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- || Enrollment closed, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Oct 9, 2018
P2, N=200, Active, not recruiting, Sponsor: Haukeland University Hospital
Trial completion date: Aug 2020 --> Mar 2021 Recruiting --> Active, not recruiting
- | Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: NeoToc: Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer (clinicaltrials.gov) - Oct 9, 2018
P2, N=80, Active, not recruiting, Sponsor: Vejle Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Apr 2020 | Trial primary completion date: Sep 2018 --> Mar 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer (clinicaltrials.gov) - Oct 5, 2018
P4, N=52, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Apr 2020 | Trial primary completion date: Sep 2018 --> Mar 2019 Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging (clinicaltrials.gov) - Oct 4, 2018
P2, N=150, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Dec 2019 --> Dec 2020
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy (clinicaltrials.gov) - Oct 2, 2018
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | taselisib (GDC-0032) / Roche
Trial primary completion date, Combination therapy, Metastases: Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (clinicaltrials.gov) - Oct 1, 2018
P1, N=76, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial primary completion date: Jan 2018 --> Apr 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer (clinicaltrials.gov) - Oct 1, 2018
P2, N=33, Active, not recruiting, Sponsor: US Oncology Research
Trial primary completion date: Jan 2018 --> Apr 2019 Trial completion date: Feb 2018 --> Dec 2019 | Trial primary completion date: Feb 2018 --> Dec 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Sep 28, 2018
P2, N=7, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Trial completion date: Feb 2018 --> Dec 2019 | Trial primary completion date: Feb 2018 --> Dec 2019 Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=65, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date: PER-ELISA: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (clinicaltrials.gov) - Sep 18, 2018
P2, N=64, Completed, Sponsor: Istituto Oncologico Veneto IRCCS
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Oct 2018 --> Jan 2018
- | Perjeta (pertuzumab) / Roche
Trial completion date: CARE-B: CARdiac Function Evaluation in Breast Cancer Patients (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=25, Recruiting, Sponsor: Swansea University
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Oct 2018 --> Jan 2018 Trial completion date: Sep 2018 --> Dec 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Sep 10, 2018
P2, N=23, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Sep 2018 --> Dec 2019 Trial primary completion date: Jun 2018 --> Dec 2018
- | paclitaxel / Generic mfg.
Enrollment change, Trial withdrawal: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Sep 4, 2018
P2, N=0, Withdrawn, Sponsor: University of Chicago
Trial primary completion date: Jun 2018 --> Dec 2018 N=60 --> 0 | Not yet recruiting --> Withdrawn
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Aug 29, 2018
P2, N=401, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=60 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Dec 2020 --> Aug 2020
- | Trial completion: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Aug 28, 2018
P3, N=444, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2020 --> Aug 2020 Active, not recruiting --> Completed
- |||| Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) - Aug 22, 2018
P2, N=144, Not yet recruiting, Sponsor: International Breast Cancer Study Group
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=88, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Mar 2018
- | Biomarker, Journal, PARP Biomarker, IO biomarker: Systemic therapy for esophagogastric cancer: targeted therapies. (Pubmed Central) - Aug 8, 2018
The anti-VEGF receptor 2 antibody, ramucirumab has been investigated as second-line therapy in 2 phase III trials, which resulted in improved survival, with subsequent FDA approval of ramucirumab in the second-line setting...PARP inhibition with olaparib, warrants further investigation, possibly in combination with other targeted therapies or immune checkpoint inhibition and in a biomarker-selected population. The identification of CLDN18.2 and its targeting with claudiximab is very promising and will be further investigated in a phase III study.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New trial, Metastases: The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-? Status in Patients With Metastatic Breast Cancer HER2 + and ER? Neg Treated With Trastuzumab + Pertuzumab + Taxane. (clinicaltrials.gov) - Aug 7, 2018
P=N/A, N=33, Not yet recruiting, Sponsor: Institut Claudius Regaud
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: PETRARCA: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (clinicaltrials.gov) - Aug 6, 2018
P2/3, N=81, Active, not recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
The identification of CLDN18.2 and its targeting with claudiximab is very promising and will be further investigated in a phase III study. Recruiting --> Active, not recruiting
- | Enrollment closed, Combination therapy: Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Aug 1, 2018
P1, N=98, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Jul 27, 2018
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Recruiting --> Active, not recruiting Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: TEAL: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (clinicaltrials.gov) - Jul 26, 2018
P2, N=24, Active, not recruiting, Sponsor: Jenny C. Chang, MD
Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2017 --> Jun 2019 | Trial primary completion date: Jun 2017 --> Jan 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Jul 20, 2018
P1/2, N=15, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | Trial completion date: Jun 2017 --> Jun 2019 | Trial primary completion date: Jun 2017 --> Jan 2019 Trial primary completion date: Dec 2018 --> Apr 2018
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change: PETRARCA: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (clinicaltrials.gov) - Jul 20, 2018
P2/3, N=80, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Trial primary completion date: Dec 2018 --> Apr 2018 N=404 --> 80